Group II Metabotropic Glutamate Receptor Agonist LY379268 Regulates AMPA Receptor Trafficking in Prefrontal Cortical Neurons

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wang, Min Juan ^a,b   Li, Yan Chun ^a   Snyder, Melissa A ^a   Wang, Huaixing ^a   Li, Feng ^b   Gao, Wen Jun ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMPA RECEPTOR; DACTINOMYCIN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR A1; GLUTAMATE RECEPTOR A2; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; LY 395756; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; IN VIVO STUDY; NERVE CELL; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL MEMBRANE; CELLS, CULTURED; DACTINOMYCIN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GLYCOGEN SYNTHASE KINASE 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SPACE; MEMBRANE PROTEINS; NEURONS; PREFRONTAL CORTEX; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, METABOTROPIC GLUTAMATE; SYNAPSINS; TRANSCRIPTION, GENETIC; XANTHENES;

EID: 84876084870     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061787     Document Type: Article

References (98)

1. Lyon L, Burnet PW, Kew JN, Corti C, Rawlins JN, et al. (2011) Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and gognition. Neuropsychopharmacology 36: 2616-2628.
2. Niswender CM, Conn PJ, (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295-322.
3. Fell MJ, McKinzie DL, Monn JA, Svensson KA, (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62: 1473-1483.
4. Conn PJ, Lindsley CW, Jones CK, (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacol Sci 30: 25-31.
5. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA, (2008) The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 22: 308-322.
6. Profaci CP, Krolikowski KA, Olszewski RT, Neale JH (2011) Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl).
7. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
8. Cartmell J, Monn JA, Schoepp DD, (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
9. Cartmell J, Monn JA, Schoepp DD, (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 148: 423-429.
10. Homayoun H, Jackson ME, Moghaddam B, (2005) Activation of metabotropic glutamate 2/3 receptors reverses the effects of nmda receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93: 1989-2001.
11. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, et al. (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72: 477-484.
12. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN, (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacol (Berl) 196: 431-440.
13. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, et al. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355.
14. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, et al. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303-309.
15. Xi D, Li Y-C, Snyder MA, Gao RY, Adelman AE, et al. (2011) Group II metabotropic glutamate receptor agonist ameliorates MK-801-induced dysfunction of NMDA receptors via Akt/GSK-3beta pathway. Neuropsychopharmacol 36: 1260-1274.
16. Bredt DS, Nicoll RA, (2003) AMPA receptor trafficking at excitatory synapses. Neuron 40: 361-379.
17. Kessels HW, Malinow R, (2009) Synaptic AMPA receptor plasticity and behavior. Neuron 61: 340-350.
18. Coyle JT, Tsai G, Goff D, (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003: 318-327.
19. Dracheva S, McGurk SR, Haroutunian V, (2005) mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res 79: 868-878.
20. Eastwood SL, Kerwin RW, Harrison PJ, (1997) Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 41: 636-643.
21. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, et al. (1995) Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 29: 211-223.
22. O'Connor JA, Hemby SE, (2007) Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. Schizophrenia Res 97: 277-288.
23. Beneyto M, Meador-Woodruff JH, (2006) Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60: 585-598.
24. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH, (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888-1902.
25. Hammond JC, McCullumsmith RE, Funk AJ, Haroutunian V, Meador-Woodruff JH, (2010) Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 35: 2110-2119.
26. Conn JP, Christopoulos A, Lindsley CW, (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
27. Lu W, Man H, Ju W, Trimble WS, MacDonald JF, et al. (2001) Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 29: 243-254.
28. Li YC, Liu G, Hu JL, Gao WJ, Huang YQ, (2010) Dopamine D1 receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons. J Neurochem 114: 62-73.
29. Hu J-L, Liu G, Li Y-C, Gao W-J, Huang Y-Q, (2010) Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Molecular Brain 3: 1-14.
30. Glynn MW, McAllister AK, (2006) Immunocytochemistry and quantification of protein colocalization in cultured neurons. Nat Protoc 1: 1287-1296.
31. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, et al. (2004) A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci 24: 4070-4081.
32. Dunn KW, Kamocka MM, McDonald JH, (2011) A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300: C723-742.
33. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng L-J, et al. (2008) Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 454: 118-121.
34. Grosshans DR, Clayton DA, Coultrap SJ, Browning MD, (2002) LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1. Nat Neurosci 5: 27-33.
35. Li YC, Xi D, Roman J, Huang YQ, Gao WJ, (2009) Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29: 15551-15563.
36. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, et al. (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol 397: R1-2.
37. Ceolin L, Kantamneni S, Barker GR, Hanna L, Murray L, et al. (2011) Study of novel selective mGlu2 agonist in the temporo-ammonic input to CA1 neurons reveals reduced mGlu2 receptor expression in a Wistar substrain with an anxiety-like phenotype. J Neurosci 31: 6721-6731.
38. Fell MJ, Johnson BG, Svensson KA, Schoepp DD, (2008) Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J Pharmacol Exp Ther 326: 209-217.
39. Dominguez C, Prieto L, Valli MJ, Massey SM, Bures M, et al. (2005) Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. J Med Chem 48: 3605-3612.
40. Lopez-Camarillo C, Luna-Arias JP, Marchat LA, Orozco E, (2003) EhPgp5 mRNA stability is a regulatory event in the Entamoeba histolytica multidrug resistance phenotype. J Biol Chem 278: 11273-11280.
41. Lopez-Rosas I, Orozco E, Marchat LA, Garcia-Rivera G, Guillen N, et al. (2012) mRNA decay proteins are targeted to poly(A)+ RNA and dsRNA-containing cytoplasmic foci that resemble P-bodies in Entamoeba histolytica. PLoS One 7: e45966.
42. Wei J, Liu W, Yan Z, (2010) Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. J Biol Chem 285: 26369-26376.
43. Stornetta RL, Zhu JJ, (2011) Ras and Rap signaling in synaptic plasticity and mental disorders. Neuroscientist 17: 54-78.
44. Lee HG, Zhu X, Casadesus G, Pallas M, Camins A, et al. (2009) The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res 1249: 244-250.
45. D'Onofrio M, Cuomo L, Battaglia G, Ngomba RT, Storto M, et al. (2001) Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem 78: 435-445.
46. Ritzen A, Mathiesen JM, Thomsen C, (2005) Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 97: 202-213.
47. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, et al. (2011) Translating Glutamate: From Pathophysiology to Treatment. Science Translational Medicine 3: 102mr102.
48. Conn PJ, Jones CK, (2009) Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacology 34: 248-249.
49. Shipe WD, Wolkenberg SE, Williams DL Jr, Lindsley CW, (2005) Recent advances in positive allosteric modulators of metabotropic glutamate receptors. Curr Opin Drug Discov Devel 8: 449-457.
50. Imre G, (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Reviews 13: 444-464.
51. Moghaddam B, Adams BW, (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
52. Moghaddam B, (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacol (Berl) 174: 39-44.
53. Krivoy A, Fischel T, Weizman A, (2008) The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur Neuropsychopharmacol 18: 395-405.
54. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, et al. (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4: 131-144.
55. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, et al. (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179: 271-283.
56. Palucha A, (2006) Are compounds acting at metabotropic glutamate receptors the answer to treating depression? Expert Opin Investig Drugs 15: 1545-1553.
57. Howes OD, Kapur S, (2009) The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 35: 549-562.
58. Meltzer HY, (1999) Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry 46: 1321-1327.
59. Conn PJ, Tamminga C, Schoepp DD, Lindsley C, (2008) Schizophrenia: moving beyond monoamine antagonists. Molecular Interventions 8: 99-107.
60. Tan HY, Callicott JH, Weinberger DR, (2007) Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17Suppl 1: i171-181.
61. Minzenberg MJ, Carter CS, (2012) Developing treatments for impaired cognition in schizophrenia. Trends in Cognitive Sciences 16: 35-42.
62. Simpson EH, Kellendonk C, Kandel E, (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65: 585-596.
63. Toda M, Abi-Dargham A, (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9: 329-336.
64. Carlsson A, Hansson LO, Waters N, Carlsson ML, (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61: 75-94.
65. Moghaddam B, (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881-884.
66. Mezler M, Geneste H, Gault L, Marek GJ, (2010) LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs 11: 833-845.
67. Schlumberger C, Schafer D, Barberi C, More L, Nagel J, et al. (2009) Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol 20: 56-66.
68. Fraley ME, (2009) Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 19: 1259-1275.
69. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, et al. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. Journal of Clinical Psychopharmacology 31: 349-355.
70. Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, et al. (2004) The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacol 47: 1135-1145.
71. Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ, (2006) Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69: 338-345.
72. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA, (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neurosci 117: 697-706.
73. Harich S, Gross G, Bespalov A, (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 192: 511-519.
74. Spinelli S, Ballard T, Gatti-McArthur S, Richards GJ, Kapps M, et al. (2005) Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl) 179: 292-302.
75. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD, (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40: 847-855.
76. Jones NC, Reddy M, Anderson P, Salzberg MR, O'Brien TJ, et al. (2011) Acute administration of typical and atypical antipsychotics reduces EEG gamma power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in gamma power. Int J Neuropsychopharmacol: 1-12.
77. Jones CA, Brown AM, Auer DP, Fone KC, (2011) The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl) 214: 269-283.
78. Amitai N, Markou A, (2010) Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. Eur J Pharmacol 639: 67-80.
79. Schoepp DD, (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299: 12-20.
80. Recasens M, Guiramand J, Aimar R, Abdulkarim A, Barbanel G, (2007) Metabotropic glutamate receptors as drug targets. Curr Drug Targets 8: 651-681.
81. Petralia RS, Wang YX, Zhao HM, Wenthold RJ, (1996) Ionotropic and metabotropic glutamate receptors show unique postsynaptic, presynaptic, and glial localizations in the dorsal cochlear nucleus. J Comp Neurol 372: 356-383.
82. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ, (1996) The metabotropic glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71: 949-976.
83. Liu XB, Munoz A, Jones EG, (1998) Changes in subcellular localization of metabotropic glutamate receptor subtypes during postnatal development of mouse thalamus. J Comp Neurol 395: 450-465.
84. Blumcke I, Behle K, Malitschek B, Kuhn R, Knopfel T, et al. (1996) Immunohistochemical distribution of metabotropic glutamate receptor subtypes mGluR1b, mGluR2/3, mGluR4a and mGluR5 in human hippocampus. Brain Res 736: 217-226.
85. Hermes ML, Renaud LP, (2011) Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus. J Pharmacol Exp Ther 336: 840-849.
86. Huang CC, Hsu KS, (2008) The role of NMDA receptors in regulating group II metabotropic glutamate receptor-mediated long-term depression in rat medial prefrontal cortex. Neuropharmacology 54: 1071-1078.
87. Huang CC, Yang PC, Lin HJ, Hsu KS, (2007) Repeated cocaine administration impairs group II metabotropic glutamate receptor-mediated long-term depression in rat medial prefrontal cortex. J Neurosci 27: 2958-2968.
88. Otani S, Daniel H, Takita M, Crepel F, (2002) Long-term depression induced by postsynaptic group II metabotropic glutamate receptors linked to phospholipase C and intracellular calcium rises in rat prefrontal cortex. J Neurosci 22: 3434-3444.
89. Groc L, Choquet D, (2006) AMPA and NMDA glutamate receptor trafficking: multiple roads for reaching and leaving the synapse. Cell Tissue Res 326: 423-438.
90. Henley JM, Barker EA, Glebov OO, (2011) Routes, destinations and delays: recent advances in AMPA receptor trafficking. Trends Neurosci 34: 258-268.
91. Derkach VA, Oh MC, Guire ES, Soderling TR, (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci 8: 101-113.
92. Di Liberto V, Mudo G, Belluardo N, (2011) mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum. Neuropharmacology 61: 638-645.
93. Endo S, Launey T, (2003) ERKs regulate PKC-dependent synaptic depression and declustering of glutamate receptors in cerebellar Purkinje cells. Neuropharmacology 45: 863-872.
94. Barry MF, Ziff EB, (2002) Receptor trafficking and the plasticity of excitatory synapses. Curr Opin Neurobiol 12: 279-286.
95. Malinow R, Malenka RC, (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126.
96. Scannevin RH, Huganir RL, (2000) Postsynaptic organization and regulation of excitatory synapses. Nat Rev Neurosci 1: 133-141.
97. Yokoi M, Kobayashi K, Manabe T, Takahashi T, Sakaguchi I, et al. (1996) Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 273: 645-647.
98. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, et al. (2004) Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 46: 907-917.